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Mechanisms of ischemic skeletal muscle regeneration mediated by 
mechanically constrained human allogeneic mesenchymal stromal cells
• Critical limb threatening ischemia (CLTI) occurs when there is blockage in a major 
blood vessel of the leg preventing complete blood perfusion to the lower limb and 
foot, resulting in rest pain, tissue death, and a high incidence of amputation.
• No effective pharmacological treatment is available for CLTI, and some patients, 
especially diabetics, are not candidates for surgical procedures.
• Injection of bone marrow-derived mononuclear cells into leg muscles of CLTI 
patients has been shown to reduce the need for amputation; however, 
mesenchymal stromal cells (MSCs), especially in 3D form (encapsulated) may be 
a more effective treatment for diabetics.
• Studies have shown that encapsulating stem cells in an alginate-based hydrogel 
has resulted in shielding from the host’s defenses and longer dwell time for the 
cells. It may also result in an alternate phenotype of the cells that could benefit 
muscle regeneration.
• Mice may be used to model CLTI by ligation and excision of the femoral artery, 
which creates a blood perfusion deficit in the leg, leading to muscle damage and 
dysfunction.
• We have adopted a polygenic mouse model of type II diabetes (TALLYHO) to 
include modeling of CLTI in order to determine the ability of MSCs & encapsulated 
mesenchymal stromal cells (eMSC) to ameliorate the tissue perfusion deficit and 
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Figure 1. Muscle pathology in the ligated, ischemic gastrocnemius muscle assessed 
by H&E staining showed significant loss of muscle fibers. Administration of MSCs or 
spheroids appeared to reverse the ischemia-induced muscle fiber loss (mag=10X).
.
•ELISA for IL-10 and IL-33 showed non-significant increases in IL-10 and 
IL-33 secretion by encapsulated vs. non-encapsulated MSCs.
•Ligated samples treated with eMSCs showed an increase in FOXP3/T-
regulatory cells.
•Culturing myoblasts with media from naked MSCs and eMSCs showed a 
change in cell morphology along with decreased proliferation compared to 
the control
•This data provides initial support for encapsulated MSCs as a viable 
treatment option for critical limb threatening ischemia and the potential 
prevention of limb amputation. 
•More work must be done in determining the mechanism behind skeletal 
muscle regeneration mediated by mechanically constrained mesenchymal 
stromal cells.
•Taken together, the results indicate that MSCs, and to a greater extent 
encapsulated MSCs, can reverse ischemic muscle damage, reduce 
inflammation, and increase muscle function by promoting regeneration of 
muscle fibers independent of tissue perfusion state.
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Figure 3. Proposed mechanism of MSC-moderated muscle regeneration after 
ischemic damage in tissue
• Determine if encapsulation process caused phenotypic changes in the production 
of IL-10 and IL-33
• Determine if eMSCs stimulate Tregulatory cells to enhance muscle regeneration




Animals and experimental timeline. All procedures were approved by the Indiana 
University School of Medicine IACUC.
• Tissue cryosections were used for immunohistochemistry (IHC) in order to assess 
muscle fiber regeneration and the presence of Tregulatory cells.
• Cells were encapsulated in 2% alginate using a centrifugation method. Cells were 
suspended in PBS, mixed with alginate, and then centrifuged through a needle into 
calcium chloride. This acted as a cross-linker, which formed a protective layer 
around the cells.
• Conditioned media from these cells along were analyzed for IL-10 and IL-33 using 
ELISA.
Figure 2. Mice were 
assessed for ischemic 
hindlimb muscle function in 
vivo by plantar flexion prior 
to cell injection (post-
ligation) and again at 30 
days post cell treatment 
(final). MSC treated mice 
exhibited significantly 
increased muscle 
contraction energy at higher 
frequency stimulations 
compared to untreated, 


















FAP-like: fibro-adipocyte progenitor like 
cells
Tregs: Foxp3+CD+ T regulatory cells
AREG: amphiregulin
M1/M2: M1 and M2-biased macrophages
hMSC: human mesenchymal stromal 
cells
Figure 4. Cells were successfully encapsulated in an alginate-based hydrogel. 
Preliminary data supporting the effects of eMSCs on muscle regeneration were 
examined by the number of centralized nuclei in the muscle fibers. These generally 
suggest newer muscles, as the nuclei of mature fibers tend to drift to the perimeter. 
Ligated samples were expected to have more centralized nuclei than their unligated 
counterparts, and ligated samples treated with eMSCs appeared to have more than 
those that were untreated. This would suggest an increase in muscle regeneration, 
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Figure 6. Immunohistochemistry was performed on 4 samples, staining for FOXP3, a 
marker for T-regulatory cells. Preliminary data demonstrated increased levels of 
FOXP3 in ligated samples treated with encapsulated MSCs. This supports our 
proposed mechanism involving T-regulatory cells in muscle regeneration.
Figure 7. Myoblasts cultured with media conditioned by naked and encapsulated 
MSCs demonstrated decreased proliferation compared to control, but both MSC-
conditioned medias caused a morphologic change in myoblasts. Cells appeared to 
elongate and potentially fuse. This suggests that MSCs may cause a differentiative 
effect on muscle progenitor cells instead of a proliferative one.
FUTURE STUDIES
•We will repeat experiments with the Buchi Encapsulator, shown below. This 
machine possess the ability to mass produce beads filled with cells on a 
larger scale more suitable for clinical trials.
•We plan to do digital droplet PCR on RNA extracted from target tissues for 
small molecules that may play a role in the results demonstrated in this 
project. This includes amphiregulin, TSG-6, and TGF-B.
•In depth characterization of the myoblasts described in Figure 7 is 
necessary in order to assess the mechanistic effect this result brings and 
how it can be utilized clinically.
•Other cells will begin to be encapsulated, including earlier passage 
versions of the cells used in the experiment, vertebral body stem cells, and 
iPSC mesodermal cells.
•Results from figures 4 and 6 will be analyzed using a scanning microscope 
in order fully quantify the magnitude of these results.
